Bausch+Lomb Results Presentation Deck
Pipeline and Upcoming Milestones¹
Ophthalmic Pharmaceuticals
Product
VYZULTA® geo-expansion
NOV032 (dry eye disease associated with
meibomian gland dysfunction)
Biosimilar candidate for Lucentis
(ranibizumab) ³
Microdose formulation of atropine ophthalmic
solution (reduction of pediatric myopia
progression in children ages 3-12)4
BAUSCH + LOMB
Status
Launched in 15 countries
FDA accepted NDA in September 2022
Xbrane withdrew aBLA5 after receiving
feedback from FDA that supplemental
information would be required
1. See slide 1 for further information on forward-looking statements.
2. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the
United States and Canada.
3. Exclusive licensing agreement with STADA Arneimittel AG and Xbrane Biopharma AB for U.S. and Canada.
Upcoming Milestone
Expected to launch in ~10 additional countries
in 2023+
PDUFA date June 28, 2023
Resubmission target date expected by end
2022
Clinical trial enrollment completion is delayed
from 4Q22 to 1H23 due to clinical trial material
availability
4. Exclusive licensing agreement with Eyenovia, Inc. for U.S. and Canada.
5. Abbreviated biologics license application.
28View entire presentation